Proactive Investors - Run By Investors For Investors

CytoDyn CEO responds to share price rise as investors get excited about leronlimab

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive Investors he's optimistic about results the company has seen in pre-clinical studies relating to a liver disease known as NASH. However, he's not sure how much CymaBay Therapeutics Inc's (NASDAQ:CBAY) disappointing mid-stage trial results in NASH contributed to pushing up CytoDyn's stock.

Pourhassan also touches on other developments within the Washington-based company including timelines to submit its BLA and recent fundraising efforts.

 
Meet Yellow Cake PLC, Avation PLC, Manolete Partners PLC and Crossword Cybersecurity Plc at our event, London , 05 September 2019. Register here »
View full CYDY profile View Profile

CytoDyn Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use